We have two categories of mAb drugs in our pipeline: Biosimilars and novel antibodies. The targeted indications include cancer, autoimmune diseases and metabolic diseases.

There are more than 10 products in our R&D pipeline. Our first product, a trastuzumab biosimilar is conducting multi-center clinical trials in China and has completed a phase I clinical trial in Australia. It's shown that our product has very good similarity profile with the originator drug. Our second product, an infliximab biosimilar, and third product, an adalimumab biosimilar, filed IND in China in 2012 and 2013, respectively. The adalimumab biosimilar also filed IND in South Korea in the end of 2013 and is expected to get clinical trial approval (CTA) there later this year.

More of the pipeline information is as shown below.